Chemomab Therapeutics Ltd. (CMMB) Institutional Ownership

Ownership Summary

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) currently has 12 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• These investors collectively held 8.0% of the company's total shares outstanding in December 2025, down from 10.2% in September 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 138.71%, with a year-over-year a decrease of 29.41% in the count of filers.
• A review of institutional activity for Chemomab Therapeutics shows 9 of 12 filers increasing their positions, while 2 reduced their stake, and 1 remained unchanged.
• Collectively, institutional investors increased their stake in Chemomab Therapeutics to 304.65K shares as of December 2025, a change that is up by 177.03K shares quarter on quarter and down 3.86Mn shares year over year.
• CITADEL ADVISORS LLC continues to be the largest institutional holder of Chemomab Therapeutics as of December 31, 2025, with a position of 103.78K shares, representing 2.72% of the company's outstanding stock.
• Among the most significant buyers of Chemomab Therapeutics during December 2025 were CITADEL ADVISORS LLC (103.78K), ADAR1 Capital Management, LLC (80.00K), KESTRA PRIVATE WEALTH SERVICES, LLC (51.71K), XTX Topco Ltd (19.01K), RHUMBLINE ADVISERS (8.35K).
• Leading sellers of Chemomab Therapeutics stock in December 2025 included MORGAN STANLEY (86.29K), JANE STREET GROUP, LLC (5.91K).
• The top 10 institutional holders of Chemomab Therapeutics for the quarter ending December 2025 included CITADEL ADVISORS LLC (103.78K), ADAR1 Capital Management, LLC (80.00K), KESTRA PRIVATE WEALTH SERVICES, LLC (51.71K), XTX Topco Ltd (19.01K), RHUMBLINE ADVISERS (17.86K), JANE STREET GROUP, LLC (15.60K), BNP PARIBAS FINANCIAL MARKETS (8.12K), MORGAN STANLEY (3.77K), GAMMA Investing LLC (2.51K), UBS Group AG (2.25K).